Mobileye May Double ADAS Sales, Formula One Sales To Accelerate, Novo Nordisk’s Ozempic Estimates Rise

In our weekly round-up of the top charts and market-moving analyst insights: Mobileye (MBLY) could double Advanced Driver-Assistance Sales (ADAS) over the next few years; Formula One Group (FWONA) is expected to see sales growth accelerate as the sport increases its number of races per season; Franco Nevada (FNV) may see gold production peak in 2025; and data pointing to the therapeutic efficacy of GLP-1 agonists for type 2 diabetes and obesity have raised future estimates for Novo Nordisk’s (NVO) Ozempic.

Mobileye Advanced Driver-Assistance Sales to Double Over Next Few Years, Say Analysts

Mobileye (MBLY) is forecasted to see Advanced Driver-Assistance Sales (ADAS) double over the next few years, according to Visible Alpha consensus. Many analysts believe demand for automobile chips will remain strong as more car manufacturers adopt ADAS features into their vehicles.

Formula 1 Sales Growth Expected To Accelerate As New Races Are Added

Analysts expect Liberty Formula One (FWONA) will see sales growth accelerate this year as the sport adds more races to extend the season and benefits from higher attendance and advertising revenue. With the addition of the Las Vegas Grand Prix, the 2023 season will feature 23 races, up from 22 in 2022. According to Visible Alpha consensus, the company is expected to add a 24th race next year.

Franco Nevada’s Gold Production Estimated to Peak in 2025, According to Analysts

Franco Nevada’s (FNV) gold production is forecasted by analysts to peak in 2025, according to Visible Alpha consensus. The company recently provided guidance suggesting slight growth in precious metal production through 2027, from current levels, if four new mines become functional.

Analysts Hike Sales Estimates for Novo’s Ozempic by More Than 2x Since 2022

Analysts have raised future estimates for Novo Nordisk’s (NVO) Ozempic sales by more than 2x since last year driven by scientific & clinical data pointing to the therapeutic utility of GLP-1 agonists for type 2 diabetes and obesity. The increased market demand is predominantly for obesity and weight loss.